Archives

Trinity Biotech Launches CGM+, AI Wearable Platform

Trinity Biotech

Trinity Biotech plc, a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, unveiled its new flagship product, CGM+, a next-generation wearable biosensor platform designed for the $260 billion AI wearables market. Now in the later stages of device development, CGM+ is Trinity’s new AI-native continuous glucose monitoring (CGM) system, combining multi-sensor data and real-time analytics to meet the evolving demands of AI-powered healthcare and wellness.

Unlike traditional CGMs focused solely on glucose monitoring, CGM+ integrates an ultra-thin minimally invasive electrochemical glucose sensor with continuous monitoring of heart activity, body temperature and physical activity—all within a single, sleek and user-friendly modular wearable device. This multimodal data stream is being optimized for real-time AI analysis, to enable a deeper, more contextual understanding of metabolic and physiological health. Trinity Biotech has identified these expanded data points as critical to gain insights into essential metabolic factors, including sleep, stress, and physical activity. Trinity Biotech’s vision is to combine medical-grade monitoring and consumer wellness insights, through the CGM+ platform, positioning Trinity Biotech at the forefront of a new category of intelligent wearables.

Also Read: Seegene debuts first unattended PCR automation at ADLM 2025

Trinity Biotech’s proprietary needle-free glucose sensor technology facilitates the collection of expanded data points from a single modular wearable device. The Company’s latest innovative design utilises this technology to provide a solution that not only reduces the number of disposable components and waste, but also significantly lowers the cost of care compared to current leading market products.

“CGM+ is not just a device—it’s a proprietary data engine we are building for the AI health ecosystem,” said John Gillard, CEO of Trinity Biotech. “We believe this technology can power the next wave of personalized, predictive, and preventative care—while opening up entirely new commercial pathways for Trinity Biotech, from device sales to AI-driven data services. It will also position us to compete well beyond traditional diagnostics, at the intersection of chronic disease management, digital health and consumer wellness.”

Purpose-Built for Real-Time AI-Driven Healthcare

As healthcare shifts toward precision medicine and continuous, real-world data collection, CGM+ is positioned to become a critical enabler of AI-based diagnostics, behavioural coaching, and chronic disease management. Now in the later stages of device development, CGM+ has been engineered from the ground up to serve as a foundational platform for AI-native health applications:

  • Comprehensive Multi-sensor Intelligence: Combines glucose, cardiovascular, thermoregulation and physical activity data for a holistic view of health and wellness.
  • Clinical and Consumer Lifestyle Use Cases: Designed to support both regulated clinical workflows and consumer wellness applications, bridging the gap between medical-grade monitoring and everyday health optimization.

Market Opportunity

  • Global CGM Market: Projected to grow from $13.28B in 2025 to $28.72B by 2030 (CAGR: 16.68%)1
  • AI in Healthcare: Forecast to reach approximately $200B by 2030, growing at a 37.6% CAGR2
  • Wearable AI: Expected to surpass $260B by 2032, growing at a 27.0% CAGR3

CGM+ is uniquely positioned at the intersection of these high-growth sectors, and is being designed to offer a differentiated solution for both clinical and consumer health markets.

Strategic Outlook and Additional Revenue Opportunities

Trinity Biotech anticipates commercial launch of CGM+ in mid-2026, opening multiple revenue streams, including device sales, AI analytics subscriptions and strategic partnerships with healthcare providers, insurers and digital health platforms.

“CGM+ is the cornerstone of our vision for AI-native health monitoring,” added Gillard. “We’re not just adding a product—we’re building a scalable platform with recurring revenue potential that we believe can drive long-term growth across clinical and consumer markets.”

Source: Globenewswire